# Chemoradiation Plus Weekly c225 Against Locoregionally Advanced Nasopharyngeal Carcinoma (NPC)

> **NCT01712919** · PHASE1,PHASE2 · COMPLETED · sponsor: **Jiangsu Cancer Institute & Hospital** · enrollment: 61 (actual)

## Conditions studied

- Nasopharyngeal Carcinoma

## Interventions

- **RADIATION:** Intensity-modulated radiotherapy
- **DRUG:** Concurrent chemotherapy with paclitaxel and nedaplatin
- **BIOLOGICAL:** Cetuximab

## Key facts

- **NCT ID:** NCT01712919
- **Lead sponsor:** Jiangsu Cancer Institute & Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05
- **Primary completion:** 2014-03
- **Final completion:** 2014-03
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2014-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01712919

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01712919, "Chemoradiation Plus Weekly c225 Against Locoregionally Advanced Nasopharyngeal Carcinoma (NPC)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01712919. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*